

Aetna Better Health®

Fax completed prior authorization request form to 855-799-2551 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

All requested data must be provided. Incomplete forms or forms without the chart notes will be returned

Pharmacy Coverage Guidelines are available at www.aetnabetterhealth.com/michigan/providers/medicaid/pharmacy

Opioids – Short-Acting and Intermediate-Acting - Michigan PDL Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently.

REQUIRED: Office notes, labs and medical testing relevant to request showing medical justification are required to support diagnosis

Member Information										
Member Name (first & last):			Date of Birth:		Gender:				Height:	
					□ Mal	е	□ Female			
Member ID:			City:	State:				Weight	:	
Prescribing Provider Inform	nation									
Provider Name (first & last): Specialty:			NPI#			DEA#	DEA#			
Office Address: City:		State:				Zip C			ode:	
Office Contact: Office Phone		Office Phone	Office Fax:							
Dispensing Pharmacy Infor	mation									
Pharmacy Name: Pharmacy Phor		Pharmacy Phone:	e: Pharmacy Fax:				:			
Requested Medication Info	rmation					•				
Specify drug:										
Are there any contraindications to formulary medications?		(if yes, please		Yes [l No	□ Nev	V	□ Co	ntinuation	
specify):							requ	uest	of red	therapy quest
Directions for Use:			Strength:				Dosage Form:			
			Quantity:	Day Supply: Duration of Th			of The	nerapy/Use:		
Medication request is NOT for an FDA- approved, or			Diagnosis: ICD-10 Code:							
compendia-supported diagnosis (circle one): Yes No										
What medication(s) have been tried and failed for this diagnosis? Please specify:										
Turn-Around Time for Review										
Standard – (24 hours) Urgent – If waiting 24 hours for standard decision could seriously harm life, health, or ability to										bility to
regain maximum function, you can ask for an expedited decision.										
Signature:										
Clinical Information										
☐ Short and Intermediate	Acting Opio	ids								
							□ No			
Does the member have any of the following to the						-L				
preferred medication(s): check all that apply			□ Contraindication or drug interactions□ History of unacceptable side effects							
Is this request for an ORAL	escribed for the r	nanag	ement	of break	kthrough c	ancer	□Yes	□No		
fentanyl product (i.e.,	ntanyl product (i.e., pain for a member established or				on immediate release and long-acting opioid					
Actiq, Fentora, or Subsys)?	ctiq, Fentora, or Subsys)? therapy?									
If YES , please answer questions to the right.	Is this reque physician?	bstances under the name and ID of the prescribing					ing	□ Yes	□ No	
	escribed by a phy	/siciar	who is	experie	enced in th	e use	□Yes	□ No		
☐ Yes of Schedule II opioids?						-				

Effective: 2/3/2025 C18543-A 1-2025 Page 1 of 3

	Has the current dosag immediate release opi	☐ Yes	□ No			
□ No	Will there be concomit	fill there be concomitant use of other inducers or inhibitors of cytochrome P450?				
s this request for Roxibond	® (Oxycodone) tablets?	Is an abuse	e deterrent formulation needed?	□Yes	□ No	
f YES , please answer the q	uestion to the right.					
☐ Yes						
□ No						
s this request for tramadol f YES , please answer the q Yes No		Does the m	nember have difficulty swallowing tablets?	□Yes	□ No	
s this request for Seglentis f YES , please the answer q ☐ Yes ☐ No		Does the prescriber attest that medication will not be used for postoperative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy?			□ No	
s the request for a codeine	or tramadol \Box	Yes □ No		□Yes	□ No	
ontaining product?			,			
	 Milligram Equivalents (N	ИМЕ)		1		
oes the member have			ed "current" cancer-related pain?	□Yes	□ No	
ny of the exceptions			d to sickle cell disease?	□Yes	□ No	
sted to the right? If YES ,	Is the member in hosp			□Yes	□ No	
o further questions. I Yes I No	Does the member reside in a long-term care facility that is exempt from reporting to or checking the State Prescription Monitoring Program (i.e., MAPS)				□ No	
	hine Milligram Equivaler	nts (MME)			1	
	Risk assessment has b		ed?	□Yes	□ No	
	Pain Medication Agree completed, and signed	□Yes	□ No			
	MAPS/NarxCare repo	□ Yes	□ No			
	Concurrently prescribe assessment the drugs	□ Yes	□ No			
Prescriber attests to all of	Concurrently prescribe	□Yes	□ No			
ne following?	Non-opioid medication	□ Yes	□ No			
] Yes	Adjuvant therapies sud behavioral therapies, o	□Yes	□ No			
] No	A toxicology screen (u appropriate intervals?	□Yes	□ No			
			wed expected results?	□ Yes	□ No	
	Member has been cou	□Yes	□ No			
	Narcan (naloxone) kit? Member has been cou when opioids are take benzodiazepines/seda	□Yes	□ No			
Has documentation been	Current documentatio including clinical justif	□Yes	□ No			
ubmitted?	Recent non-opioid me cannot be used?	□Yes	□ No			
] Yes] No	Documentation includ acting) and when the r	□Yes	□ No			
	Has the member's cur	☐ Yes	□ No			
	Pregnant patients on of followed by an OB/GY submitted with reques	□Yes	□ No			
Renewal						
Has documentation been s showing the member contin		es 🗆 No	Has documentation of taper plan or rationale why taper is not appropriate been submitted?	□ Yes	□ No	

Additional information the prescribing provider feels is important to this review. Plea	se specify below or submit medical records
Signature affirms that information given on this form is true and accurate and reflects	office notes.
Prescribing Provider's Signature:	Date:

Please note: Incomplete forms or forms without the chart notes will be returned

Office notes, labs, and medical testing relevant to the request that show medical justification are required. Standard turnaround time is 24 hours. You can call 855-300-5528 to check the status of a request.

Effective: 2/3/2025 C18543-A 1-2025 Page 3 of 3